<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839875</url>
  </required_header>
  <id_info>
    <org_study_id>MON564.130.1</org_study_id>
    <nct_id>NCT03839875</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Gynomax® XL Ovule</brief_title>
  <acronym>Gyno-Türk</acronym>
  <official_title>A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exeltis Turkey</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monitor CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exeltis Turkey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial
      vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this
      open label, single-arm, multicentral study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Actual">August 9, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete response to treatment</measure>
    <time_frame>10 Days after completion of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with partial response to treatment</measure>
    <time_frame>10 Days after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no response to treatment</measure>
    <time_frame>10 Days after completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Trichomonal Vaginitis</condition>
  <condition>Bacterial Vaginosis</condition>
  <condition>Candidal Vulvovaginitis</condition>
  <condition>Mixed Vaginal Infections</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gynomax® XL Vaginal Ovule</intervention_name>
    <description>tioconazole, tinidazole, lidocaine</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with age ≥ 18 and ≤ 45 years

          -  Patients requiring treatment for bacterial vaginosis, candidal vulvovaginitis or mixed
             infections according to the investigator's decision

          -  Signed informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to active ingredients of the study medications

          -  Vaginismus, endometriosis, dyspareunia

          -  Detection of urinary tract infection in urinalysis

          -  Acute or chronic infections such as pancreatitis, hypertriglyceridemia, liver
             diseases, benign or malign tumors

          -  Usage of herbal medicines that interfere with microsomal enzymes, especially
             cytochrome P450 (phenytoin, phenobarbital, primidone, carbamazepine, rifampicin,
             topiramate, felbamate, griseofulvin, HIV protease inhibitors such as ritonavir,
             nucleoside reverse transcriptase inhibitors such as efavirenz)

          -  History of cardiovascular event

          -  Advanced hypertension and diabetes

          -  Presence or known risk or of venous or arterial thromboembolism

          -  Undiagnosed abnormal vaginal bleeding, bleeding disorders, genital tumors

          -  Use of drugs containing ombitasvir / paritaprevir / ritonavir or dasabuvir during or
             two weeks before initiation of the study

          -  Pregnancy and/or breastfeeding

          -  Participation in any other trial 30 days before initiation of the study

          -  Postmenopausal women

          -  Abuse of alcohol

          -  Usage of medications containing acenocoumarol, anisindione, dicoumarol, phenindione,
             phenprocoumon, warfarin, cholestyramine, cimetidine, cyclosporine, disulfiram,
             fluorouracil, fosphenitoin, ketoconazole, lithium, rifampin, tacrolimus or propranolol

          -  Presence of a sexually transmitted disease such as syphilis, gonorrhea, etc. according
             to the investigators decision
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ege University Family Planning and Infertility Application and Research Centeraştırma Merkezi</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Trichomonas Vaginitis</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

